Health

#SFHS2608458VNotice on the Prices of Pharmaceutical Specialties Published under Article L. 162-16-5 of the Social Security Code

🇫🇷France··Other·Low Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This notice announces the tax-free sale prices of specific pharmaceutical products for healthcare establishments in France. It affects hospitals purchasing the drugs Micafungine ACC 100MG and Micafungine ACC 50MG from ACCORD HEALTHCARE FRANCE SAS, with prices set at €89.010 and €55.062 respectively.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Announced new prices for pharmaceutical specialties
  • Applies to Micafungine ACC 100MG and 50MG products
  • Prices are tax-free for healthcare establishments

Obligations

What this law requires

high

ACCORD HEALTHCARE FRANCE SAS must sell Micafungine ACC 100MG at the tax-free price of €89.010 per unit to healthcare establishments

ACCORD HEALTHCARE FRANCE SAS
operational
high

ACCORD HEALTHCARE FRANCE SAS must sell Micafungine ACC 50MG at the tax-free price of €55.062 per unit to healthcare establishments

ACCORD HEALTHCARE FRANCE SAS
operational
high

Healthcare establishments must apply the published tax-free prices (€89.010 for 100MG and €55.062 for 50MG) when purchasing these pharmaceutical specialties from ACCORD HEALTHCARE FRANCE SAS

Healthcare establishments in France
operational
high

ACCORD HEALTHCARE FRANCE SAS must comply with the economic convention between the health products economic committee (CEPS) and the company regarding these pharmaceutical prices

ACCORD HEALTHCARE FRANCE SAS
operational

Affected Parties

HospitalsACCORD HEALTHCARE FRANCE SAS

Tags

pharmaceuticals,pricing,healthcare